Nitric oxide-driven modifications of lipoic arm inhibit α-ketoacid dehydrogenases

Gretchen L Seim
Steven V John
Nicholas L Arp
Zixiang Fang
David J Pagliarini

See next page for additional authors
Authors
Gretchen L Seim, Steven V John, Nicholas L Arp, Zixiang Fang, David J Pagliarini, and Jing Fan
Nitric oxide-driven modifications of lipoic arm inhibit α-ketoacid dehydrogenases

Gretchen L. Seim1,2, Steven V. John1,3, Nicholas L. Arp3,2, Zixiang Fang4, David J. Pagliarini4,5,6 and Jing Fan1,2,3

Pyruvate dehydrogenase complex (PDHC) and oxoglutarate dehydrogenase complex (OGDC), which belong to the mitochondrial α-ketoacid dehydrogenase family, play crucial roles in cellular metabolism. These multi-subunit enzyme complexes use lipoic arms covalently attached to their E2 subunits to transfer an acyl group to coenzyme A (CoA). Here, we report a novel mechanism capable of substantially inhibiting PDHC and OGDC: reactive nitrogen species (RNS) can covalently modify the thiols on their lipoic arms, generating a series of adducts that block catalytic activity.

S-Nitroso-CoA, a product between RNS and the E2 subunit’s natural substrate, CoA, can efficiently deliver these modifications onto the lipoic arm. We found RNS-mediated inhibition of PDHC and OGDC occurs during classical macrophage activation, driving significant rewiring of cellular metabolism over time. This work provides a new mechanistic link between RNS and mitochondrial metabolism with potential relevance for numerous physiological and pathological conditions in which RNS accumulate.

Mitochondrial α-ketoacid dehydrogenases are a family of multi-subunit enzyme complexes that includes PDHC, OGDC, and branched-chain ketoacid dehydrogenase complex (BCKDC). These enzymes function at critical crossroads in the metabolic network, controlling carbohydrate and amino acid metabolism, mitochondrial energy production and cellular redox state. Specifically, PDHC catalyzes the conversion of pyruvate to acetyl-CoA, and OGDC catalyzes the oxidation of α-ketoglutarate (α-KG) to succinyl-CoA; thus, both control the entrance of major carbon sources into the tricarboxylic acid (TCA) cycle. α-Ketoacid dehydrogenase complexes share similar catalytic mechanisms involving coupled reactions with three subunits. The E1 subunit decarboxylates an α-ketoacid and transfers the corresponding acyl group to a thiamine pyrophosphate cofactor. This acyl group is then transferred to the E2 subunit (dihydrolipoamide acyltransferase), which uses a lipoic arm covalently attached to a lysine residue to transfer the acyl group to the thiol of CoA, producing an acyl-CoA. As a result, the lipoic arm becomes reduced. The E3 subunit (dihydrolipoamide dehydrogenase) then reoxidizes the lipoic arm, coupled to NADH production.

Regulation of α-ketoacid dehydrogenases is important for numerous physiological processes including metabolic switching during fasting and feeding, the response to hypoxia, and differentiation and has broad relevance to many diseases including cardiovascular conditions, cancer, diabetes, and inborn errors of metabolism. The activity of α-ketoacid dehydrogenases is controlled through layers of transcriptional, post-translational, and metabolite-driven mechanisms. The best-known mechanisms include inhibitory phosphorylation of the E1 subunit of PDHC and BCKDC, which is controlled by specific kinases and phosphatases. Post-translational modifications of the E2 and E3 subunits, including modification of the E2 subunit’s lipoic arms by glutathionylation, reactive oxygen species (ROS), and lipid peroxidation products, as well as cysteine oxidation and nitrosylation of the E3 subunit, have also been reported to modulate the activity of α-ketoacid dehydrogenase complexes.

We recently found that PDHC and OGDC become profoundly inhibited in macrophages upon stimulation with the classical activation signals lipopolysaccharide (LPS) and interferon-γ (IFN-γ). This inhibition

1Morgridge Institute for Research, Madison, WI, USA. 2Department of Nutritional Sciences, University of Wisconsin-Madison, Madison, WI, USA. 3Cellular and Molecular Biology Graduate Program, University of Wisconsin-Madison, Madison, WI, USA. 4Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO, USA. 5Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO, USA. 6Department of Genetics, Washington University School of Medicine, St. Louis, MO, USA. *e-mail: jfan@morgridge.org
Article https://doi.org/10.1038/s41589-022-01153-w

Fig. 1 | NO production temporally correlates with the loss of catalytically active lipoic arm and PDHC and OGDC activity. a, PDHC and OGDC activity, DLAT and DLST level and their lipoylation state, and iNOS level in RAW 264.7 cells stimulated with LPS + IFN-γ for the indicated time. b, PDHC activity, iNOS expression, protein lipoylation state and total DLAT level in murine BMDM stimulated with LPS + IFN-γ for the indicated time. c–e, The abundance of intracellular acetyl-CoA (c), succinyl-CoA (d) and citrulline (e) in BMDM stimulated with LPS + IFN-γ for the indicated time. ND, not detected. All bars and error bars represent mean ± s.d. (n = 3 distinct samples). Data were analyzed using one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test. Bars not sharing a letter/number are significantly different (P < 0.05) from one another. Exact P values for each comparison are available in the source data. a, b. On lipoic acid western blots, specific bands corresponding to the lipoic arm of DLAT and DLST are labeled based on the expected molecular mass and the position of DLAT and DLST bands, as determined by total DLAT/DLST blots. The blots shown are representative of at least two independent experiments.

We noticed that the decrease in the functional lipoic arm and enzyme activity are temporally correlated with the increase in iNOS expression to generate RNS for pathogen killing 12.

We recently discovered that stimulation of macrophages by LPS + IFN-γ drives substantial TCA cycle remodeling, impacting the abundance of important immunomodulatory metabolites. We found that such PDHC and OGDC inhibition is largely due to loss of the catalytically active lipoic arm on their E2 subunits11. (Note, here we use ‘lipoic arm’ to refer to both the oxidized and reduced lipoic moiety, that is ‘lipooyl moiety’ and ‘dihydrolipooyl moiety,’ respectively.) The molecular mechanism causing this loss was unclear.

Here we show that RNS, which macrophages produce in large amounts upon classical activation, are capable of substantially inhibiting PDHC and OGDC by causing a series of covalent S-modifications on their lipoic arm. CoA, the thiol-containing natural substrate for PDHC and OGDC’s E2 subunits11. (Note, here we use ‘lipoic arm’ to refer to both the oxidized and reduced lipoic moiety, that is ‘lipooyl moiety’ and ‘dihydrolipooyl moiety,’ respectively.) The molecular mechanism causing this loss was unclear.

Here we show that RNS, which macrophages produce in large amounts upon classical activation, are capable of substantially inhibiting PDHC and OGDC by causing a series of covalent S-modifications on their lipoic arm. CoA, the thiol-containing natural substrate for PDHC and OGDC’s E2 subunits, can deliver modifications to the lipoic arm, making this mechanism particularly efficient and specific. In activated macrophages, inhibiting RNS production significantly rescues the loss of PDHC and OGDC’s functional lipoic arms and activities, and alters TCA cycle remodeling. This work reveals a novel mechanism regulating lipoic arm-dependent enzymes and provides a new mechanistic link between RNS and cellular metabolism that has broad implications for physiological and pathological conditions involving RNS accumulation.

**Results**

**NO drives PDHC and OGDC inhibition by altering lipoic arm**

We recently discovered that stimulation of macrophages by LPS + IFN-γ led to a profound inhibition of PDHC and OGDC over time16. This inhibition is in large part due to the loss of the functional lipoic arm on their E2 subunits, dihydrolipoamide acetyl transferase (DLAT) and dihydrolipoamide succinyl transferase (DLST), respectively, although total DLAT and DLST levels remain steady (Fig. 1a,b), and the expression of E1 and E3 subunits, as well as cell viability, do not decrease16.

Upon classical activation, macrophages quickly express inducible nitric oxide synthase (iNOS) to generate RNS for pathogen killing12. We noticed that the decrease in the functional lipoic arm and enzyme activity are temporally correlated with the increase in iNOS expression in two macrophage cell models, RAW 264.7 cells (Fig. 1a) and murine bone marrow-derived macrophages (BMDM) (Fig. 1b). Consistently, the intracellular levels of PDHC’s product acetyl-CoA and OGDC’s product succinyl-CoA also decreased over time (Fig. 1c,d), in temporal correlation with the accumulation of citrulline, the product of iNOS (Fig. 1c). Furthermore, across different stimulation conditions, we found that only when iNOS activity was considerable (indicated by noticeable citrulline accumulation), was there substantial loss of functional lipoic arms on PDHC and OGDC’s E2 subunit (Extended Data Fig. 1). Together, these results demonstrate a correlation between nitric oxide (NO) production and the loss of PDHC and OGDC’s functional lipoic arms and enzyme activities.

To test the causal relationship behind this correlation, we first treated RAW 264.7 cells with the iNOS inhibitor 1400W. Inhibition of iNOS significantly protected cells against the stimulation-induced loss in functional lipoic arms and PDHC activity (Fig. 2a). Consistently, iNOS inhibition also rescued the contribution of PDHC to acetyl-CoA production in stimulated macrophages, as reflected by the incorporation of [U-13C]glucose into acetyl-CoA, especially in the labeled forms that presumably involve labeling on the acetyl-moiety (for example, M + 7 labeled form) (Fig. 2b). This rescue of acetyl-CoA labeling was accompanied by a rescue of labeling in the downstream TCA cycle metabolites citrate and succinate. These data indicate that NO has a substantial impact on the remodeling of glucose oxidation through the TCA cycle stimulated macrophages (Fig. 2b). We further tested the impact of NO using a genetic knockout of iNOS (Nos2−/−). Like 1400W treatment, iNOS knockout in RAW 264.7 cells significantly rescued the loss of PDHC and OGDC activity and their functional lipoic arms that occurs upon stimulation (Fig. 2c), and rescued the labeling incorporation from [U-13C]glucose into acetyl-CoA, citrate and succinate (Fig. 2d). Similar rescue of glucose labeling into these TCA cycle intermediates was also observed in stimulated Nos2−/− BMDM cells (Extended Data Fig. 2).

We also investigated the role of NO in regulating OGDC activity in cells using a [5-13C]glutamine tracer. [5-13C]Glutamine generates 13C-labeled α-KG, whose further conversion to malate through the TCA cycle is dependent on OGDC activity. In wild-type cells, as previously shown, the relative labeling incorporation into malate compared with α-KG decreases with LPS + IFN-γ stimulation, consistent with reduced
OGDC activity. This decrease, however, is prevented by iNOS knockout (Fig. 2e). These data collectively show that inhibition of PDHC and OGDC, loss of their functional lipoic arms, and the resulting impact on TCA cycle rewiring in activated macrophages are substantially dependent on NO production.

Next, using treatment with NO donors, we tested whether NO was sufficient to cause the loss of PDHC and OGDC activity and their functional lipoic arms. Treating cell lysates with S-nitrosoglutathione (GSNO) or S-nitroso-cysteine ethyl ester (EtCys-SNO) at concentrations as low as 50 µM caused significant inhibition of OGDC activity, as well as decreased levels of the functional lipoic arm relative to total DLST (Fig. 2f). Moreover, treating unstimulated macrophages with the NO donor diethylenetriamine NONOate (DETA NONOate) caused a reduction in functional lipoic arm and PDHC activity without significantly reducing total DLAT level or causing cellular toxicity (Fig. 2g and Supplementary Fig. 1), recapitulating what is observed in stimulated macrophages. Treatment with NO donor also reversed the 1400W-mediated protection of PDHC’s lipoic arm and activity in stimulated macrophages (Fig. 2g). Together, these results demonstrate that NO plays a key role in the loss of functional lipoic arms and the profound inhibition of PDHC and OGDC.

RNS cause inhibitory S-modifications of the lipoic arm

We next investigated the molecular mechanism by which NO leads to loss of the functional lipoic arm. To evaluate the possibility that NO may inhibit lipoic arm installation or increase lipoic arm removal
between thiols and RNS. These products included: (1) at least three their exact masses and isotopic distributions, and the likely structures. The formulas of the most abundant products were identified based on did not react with RNS (Fig. 3a,b). Untargeted LC–MS analysis revealed with RNS. By contrast, oxidized LA, which does not contain free thiols, we found that DHLA was significantly depleted after 3 h incubation ing their lipoic arms. To evaluate the chemical reactivity of the lipoic arm to RNS, we first incubated free LA (C\textsubscript{8}H\textsubscript{14}O\textsubscript{2}S\textsubscript{2}) and its reduced form, dihydrolipoic acid (DHLA, C\textsubscript{8}H\textsubscript{14}O\textsubscript{2}S\textsubscript{2}), with NO donors, GSNO (which can release NO as well as react through trans-nitrosylation)\textsuperscript{13,14}, dipropenylamine NONOate (DPTA NONOate) or propylamine NONOate (PAPA NONOate). We found that DHLA was significantly depleted after 3 h incubation with each NO donor, suggesting DHLA can nonenzymatically react with RNS. By contrast, oxidized LA, which does not contain free thiols, did not react with RNS (Fig. 3a,b). Untargeted LC–MS analysis revealed that the reaction between DHLA and RNS yielded a variety of products. The formulas of the most abundant products were identified based on their exact masses and isotopic distributions, and the likely structures were assigned based on previous knowledge of the chemical reactions between thiols and RNS\textsuperscript{15–17}. These products included: (1) at least three distinct species, separated by their retention time, with the formula C\textsubscript{8}H\textsubscript{14}O\textsubscript{2}S\textsubscript{N}, which correspond to S-nitrosylation of either thiol of DHLA, a hydroxyl-disulfenamide or a thiol-sulfenamide (R1); (2) C\textsubscript{8}H\textsubscript{14}O\textsubscript{2}S\textsubscript{N}, corresponding to a disulfenamide product (R2); and (3) C\textsubscript{8}H\textsubscript{14}O\textsubscript{2}S\textsubscript{2}, corresponding to a thiosulfinate (R3) (Fig. 3c). These products are consistently observed in reactions with all three NO donors, although their abundances can vary depending on the specific RNS involved and RNS-to-thiol ratio\textsuperscript{16,17}. We next examined whether similar reactions can occur nonenzy- matically when incubating NO donors with a synthesized dihydrolipooylated DLAT peptide (LSEGDLLAEIETDK(dihydrolipoyl)ATIGFEVQEEGYLAK). We found that reaction with all three NO donors quickly depleted the peptide, generating a series of thiol modification products (Fig. 3d and Supplementary Fig. 3), corresponding to those observed in the free DHLA experiment (R1–R3). We then tested whether PDHC could be inhibited by RNS in vitro, by incubating purified PDHC with NO donors. Because the results above showed that the reduced dihydrolipoic moiety, but not the oxidized lipoic moiety, can react with RNS, we also included different combina- tions of substrates during the incubation to manipulate the redox state of the lipoic arm. Based on the established catalytic mechanism of PDHC, inclusion of pyruvate and CoA can drive conversion of the lipoic moiety to its reduced form, and further addition of NAD\textsuperscript{+}, the substrate of the E3 subunit, allows the lipoic arm to cycle between the reduced and oxidized forms (Fig. 3e). We found that when PDHC was incubated with NO donors in the presence of pyruvate and CoA, its activity was profoundly inhibited, accompanied by reduced functional lipoic arm levels. By contrast, incubation of PDHC with NO donors alone had a minimal impact on its activity (Fig. 3f). These results show that RNS can cause substantial inhibition of PDHC, and this inhibition requires the availability of thiols on the lipoic arm, indicating a specific mechanism involving lipoic thiol modification. Consistent with this model, when NAD\textsuperscript{+} was also added during the incubation period, and the lipoic arm was therefore in the reduced form for a shorter time, PDHC was also profoundly inhibited by RNS, but to a slightly lesser extent (Fig. 3f).

5-Nitroso-CoA efficiently delivers modifications to the lipoic arm

The specificity and stoichiometry of post-translational modifications have been long key topics in protein research\textsuperscript{18–20}. Because most known ROS- and RNS-driven modifications are nonenzymatic, it is important to understand how some modifications can be sufficiently enriched at functionally relevant sites to impart important biological impacts. In this case, we found the NO-driven inhibition of PDHC can be almost complete both in vitro and in cells. We hypothesized that the key factor underlying such efficiency is CoA, the thiol-containing natural substrate for a ketoacid dehydrogenases’ E2 subunits (Fig. 4a). It has been shown previously that low molecular mass thiol-containing metabolites, particularly glutathione and CoA, play an important role in mediating cysteine nitrosylation in cells by forming low molecular mass SNOs\textsuperscript{19–22}. Indeed, we found that in the presence of various NO donors, 5-Nitroso-CoA (SNO-CoA) is quickly and nonenzymatically formed from CoA (Extended Data Fig. 3a,b) (potential enzymatic forma- tion may contribute further to SNO-CoA availability in cells). Based on the structural similarity between SNO-CoA and CoA, it is conceivable that SNO-CoA can efficiently bind to the E2 subunit and deliver RNS modifications to the lipoic arm in a targeted manner. To test this hypothesis, we first examined whether CoA is required for RNS-driven PDHC inhibition. Although incubation of PDHC with pyruvate alone would also generate one free thiol on the lipoic arm, inclusion of pyruvate without CoA was not sufficient for the substan- tial inhibition of PDHC by NO donors (Fig. 4b). Alternatively, adding NADH to PDHC can generate reactive thiols on the lipoic arm through reversed reaction of the E3 subunit (Fig. 4a, indicated by green arrow). When purified PDHC was incubated with NO donors in the presence of both NADH and CoA, we observed near-complete inhibition. By contrast, when either CoA or NADH was omitted during the incuba- tion period the inhibition was much weaker (Fig. 4c). These results demonstrate that RNS-driven inhibition of PDHC depends on both the availability of reactive thiols on the lipoic arm and the presence of CoA. This requirement for CoA could, as hypothesized, reflect a role for SNO-CoA in delivering the modifications, or it is possible that CoA binding to the E2 subunit induces a conformational change allowing the lipoic arm to be more effectively modified. To directly test the ability of SNO-CoA to inhibit PDHC, we incu- bated purified PDHC with SNO-CoA without additional CoA or other NO donors. SNO-CoA caused substantial inhibition in the presence of either pyruvate or NADH (Extended Data Fig. 3c). The inhibition of PDHC by SNO-CoA is dose-dependent, with 100 and 300 mM SNO-CoA causing ~50% and >95% inhibition after 1 h incubation (Fig. 4d), showing that SNO-CoA is a potent inhibitor of PDHC. If SNO-CoA binding to the E2 subunit is key to the efficient delivery of inhibitory modifications, we would predict that competing with SNO-CoA binding can protect PDHC activity. Indeed, we found that addition of CoA reduced the inhibition of PDHC by SNO-CoA (20 µM) in a dose-dependent manner, with 0.5 and 4 mM CoA preventing ~50% and ~75% of the activity loss, respectively (Fig. 4c). Similarly, addition of acetyl-CoA, the natural product of DLAT which binds to the same site, also protected PDHC from inhibition by SNO-CoA in a dose-dependent manner.
controls, a one-sample two-sided Student’s t-test was used to test whether the mean was significantly different from 0. e. Schematic of experimental workflow and the catalytic mechanism of PDHC. After incubation with the indicated compounds, enzyme activity was measured after dilution into assay buffer containing all substrates at saturating levels. f. Activity and lipoylation state of purified PDHC following 3 h incubation (room temperature) with NO donors in the presence or absence of the indicated substrates. Independent experiments were combined and normalized to their own control (PDHC incubated in buffer). Bar graph with error bars represents mean ± s.d. n = 4 distinct samples for DPTA NONOate treatment, otherwise n = 5 distinct samples. For comparison between NO donor-treated samples, P values were determined by ANOVA followed by Tukey’s post hoc test. For comparison with the control (PDHC incubated in buffer), P values were determined using a one-sample t-test to determine whether the mean is significantly different from 1. The shown western blot is representative of two independent experiments.
arrows show that NADH can generate reduced lipoic arm via reversed E3 subunit and delivers modifications to the lipoic arm, blocking its catalytic cycle. Green CoA, the thiol-containing natural substrate of the E2 subunit, reacts with RNS concentration resulted in increasing SNO-CoA formation. However, when the CoA concentration was relatively high compared with GSNO, increasing the GSNO concentration resulted in increasing SNO-CoA formation. When the CoA concentration is low, increasing GSNO caused SNO-CoA formation to first increase then decrease, with the yield of other products becoming more dominant when GSNO was present in large excess (Supplementary Fig. 4a–c). We found that the inhibition efficiency of PDHC showed a strong correlation with the SNO-CoA/GSNO ratio, but not with the total level of GSNO across these conditions. When the CoA level is low, upon increasing the level of GSNO, PDHC inhibition first increased then substantially decreased; however, when the CoA level is high, PDHC inhibition remained strong across the dose curve (Supplementary Fig. 4d). Consistent with the observation that GSNO in a great excess of CoA reduces PDHC inhibition, we also found that although a low concentration of SNO-CoA in the presence of NADH can cause substantial inhibition of PDHC, adding a larger amount of the NO donor PAPA NONOate on top made the overall inhibition weaker (Fig. 4f). This seemingly counterintuitive decrease in inhibition correlates with a decreased level of SNO-CoA (Fig. 4g). Overall, these results show that the level of SNO-CoA, rather than other NO donors, has primary control of the inhibition, supporting a CoA-delivered modification mechanism.

Reversibility and effects of RNS-driven PDHC/OGDC inhibition
Our data revealed that RNS can cause a diversity of thiol modifications on the lipoic arms (Fig. 3). Previous research has shown that the reversibility of different thiol modifications can vary. Modifications such as S-nitrosylation are generally reversible, regulatory and can be removed
the RNS-driven inhibition of α-ketoacid dehydrogenases is partially lysates to various degrees (Fig. 5c). Together, these results show that and lysate that had been treated with NO donor in vitro). As with purified PDHC that had been inhibited by incubation with this using purified PDHC that had been incubated in vitro with the indicated combination of substrates and NO donors and substrates (Fig. 5a), or with SNO-CoA and NADH (Fig. 5b). DTT treatment generally resulted in the partial recovery of PDHC activity. However, the degree of recovery varied depending on the specific inhibition conditions, including the type of NO donor used, the substrates present during incubation (for example, whether NAD+ is present) (Fig. 5a) and the concentration of SNO-CoA (Fig. 5b). We next tested the extent to which treatment with DTT can recover OGDC activity in cell lysates (lysat from LPS + IFN-γ stimulated macrophage, and lysate that had been treated with NO donor in vitro). As with purified PDHC, DTT treatment partially recovered OGDC activity in cell lysates to various degrees (Fig. 5c). Together, these results show that the RNS-driven inhibition of α-ketoacid dehydrogenases is partially reversible, and the exact reversibility is condition-dependent. This likely reflects that overall inhibition of these enzymes is due to a diversity of inhibitory thiol modifications, whose composition varies with specific conditional parameters.

Next, using an acute stimulation model of macrophages we investigated whether and when RNS-driven PDHC and OGDC inhibition could be recovered in cells. In the experiments shown in Fig. 1, macrophages were cultured in the continual presence of LPS + IFN-γ (continual stimulation), which resulted in drastic and sustained induction of iNOS and NO production throughout the time course of the experiment. Alternatively, when macrophages were exposed to only LPS + IFN-γ for 2 h, then switched to fresh media without stimuli (acute stimulation), iNOS expression was only transiently induced, peaking at around 6 h and then returning to baseline throughout the rest of the time course (Fig. 5d), thus allowing for possible PDHC and OGDC recovery. Consistent with continual stimulation (Fig. 1), upon acute stimulation we also observed a decrease in PDHC and OGDC activity and their functional lipoic arms starting soon after iNOS induction and peaking at 24 h post-stimulation. However, at later time points, after iNOS levels had
subsidied, we observed the recovery of both PDHC and OGDC activity and their functional lipoic arms (Fig. 5d).

The kinetics of PDHC and OGDC inhibition and recovery can have important impacts on cellular metabolism and influence cell functions by altering the levels of signaling or regulatory metabolites. Several recent studies have highlighted that in macrophages, itaconate and succinate can orchestrate immune functions via mechanisms that include the stabilization of transcription factor hypoxia-inducible factor-1α (HIF-1α), modulation of nuclear factor-erythroid factor 2-related factor 2 (NRF2) and activating transcription factor 3 (ATF3) pathways, regulation of inflammasome activation, and modulation of the epigenetic landscape. At early time points following LPS + IFN-γ activation, macrophages increase the expression of aconitate decarboxylase 1 (ACOD1 or IRG1), the enzyme that produces itaconate, causing itaconate to accumulate; itaconate-mediated inhibition of succinate dehydrogenase also causes succinate to accumulate. We have previously shown that during continual stimulation following this initial accumulation, strong inhibition of PDHC and OGDC drives a decrease in itaconate and succinate levels by greatly restricting the influxes supporting their production. Upon acute stimulation in RAW 264.7 cells, we found that itaconate and succinate levels showed a similar trend, in which they initially accumulate and then decrease over the first 24–32 h (Fig. 5e), reflecting a similar rapid increase in ACOD1 expression and a gradual decrease in PDHC and OGDC activity during this period (Figs. 1a and 5d). Interestingly, in contrast to continual stimulation, under which these metabolites stay low for the rest of the time course (Fig. 1a), -48 h after acute stimulation itaconate and succinate showed a strong second accumulation (Fig. 5e), consistent with the recovery of PDHC and OGDC activity at this time (Fig. 5d).

Another important TCA cycle-derived regulatory metabolite is 2-hydroxy-glutarate (2-HG). In various other cell types, accumulation of 2-HG has been associated with OGDC inhibition or defects in the lipoic arm, and 2-HG accumulation can impact cell functions through stabilization of HIF and regulation of epigenetic remodeling. We found that 2-HG levels accumulated across the continual stimulation time course, but were only slightly increased upon acute stimulation, peaking at 12 h (Figs. 1a and 5e).

To specifically test the role of NO in these metabolic changes, we measured the level of itaconate, succinate and 2-HG in Nos2−/− RAW 264.7 cells continually stimulated for 48 h. In stark contrast to wild-type cells, where itaconate and succinate fell below baseline at this time point, in Nos2−/− cells, itaconate and succinate remained highly elevated (Fig. 5f). This is consistent with our model that the decrease in itaconate and succinate is caused by NO-driven PDHC and OGDC inhibition, and is consistent with data showing that PDHC and OGDC activity and carbon incorporation from glucose and glutamine into the TCA cycle are rescued by iNOS knockout (Fig. 2c–e). iNOS knockout also prevented the accumulation of 2-HG upon stimulation (Fig. 5f). Together, these results demonstrate that the changes in these regulatory metabolites upon stimulation are impacted by NO production.

As mentioned above, one common mechanism by which itaconate, succinate and 2-HG impart their regulatory function, is via stabilization of HIF-1α by inhibiting its prolyl hydroxylase51–54. We have previously shown that during continual stimulation, the early transient increase in succinate and itaconate leads to a transient increase in HIF-1α stability and level. This was followed by a decrease in HIF-1α levels as PDHC and OGDC become inhibited and itaconate and succinate levels fall. Similarly, here we found that upon acute stimulation of RAW 264.7 cells, HIF-1α levels first increased then decreased within the first 48 h. However, there was a second increase in HIF-1α levels at 72 h (Fig. 4g), following the second increase in itaconate and succinate. This suggests the fluctuation in succinate, itaconate and 2-HG, could influence the dynamic changes in HIF-1α upon both continual and acute stimulation. HIF-1α has been shown to promote proinflammatory phenotypes in macrophages. This points to a possible mechanism by which the changing activity of PDHC and OGDC may contribute to tuning of the immune response.

Discussion

In this work, we revealed that RNS can cause substantial inhibition of PDHC and OGDC, via a novel mechanism involving covalent thiol modification of their lipoic arms. We also demonstrate that CoA can mediate targeted delivery of RNS modifications onto the lipoic arm, making this mechanism particularly specific and efficient.

The experiments shown here provide strong biochemical evidence that RNS can cause inhibitory lipoic modifications and lay out several lines of supportive evidence that suggest an important role for this mechanism in metabolic rewiring during macrophage activation. However, a limitation of this work is the lack of direct measurement of these lipoic modifications in cells. Western blot-based measurement of the lipoic arm cannot distinguish whether the loss of detection is due to loss or modification of the lipoic arm, nor can it distinguish the specific types of modifications. The measurement is further complicated by the fact that multiple lipoylation sites on α-ketoacid dehydrogenase complexes cannot be separated on a gel, and that the antibody may still have some binding affinity toward some of the modified forms of the lipoic arm. We made substantial efforts to measure these RNS-driven lipoic modifications in cell lysates by LC–MS. However, the relative low abundance of DLAT and DLST, the chemical complexity of lipoic modifications, and stability issues with some of these modifications made measurement in cellular samples very technically challenging. Future development of a more sensitive method targeting the lipoic modifications is needed. With the help of such a method, one future direction is to quantitatively characterize how much each of the lipoic adducts is formed as a function of the RNS-thiol ratio, time, chemical environment and so on. In this study, we identified several types of covalent thiol modifications that have not previously been reported on the lipoic group. Although they should all block the lipoic arm’s catalytic activity, their reversibility can differ. Future work will also mechanistically address how the kinetics of PDHC and OGDC inhibition and recovery under specific conditions are affected by the quantitative distribution of these lipoic adducts, and to what extent the reduction of RNS-mediated modifications and the general turnover of PDHC and OGDC contribute to their recovery.

Here, we showed that PDHC and OGDC are profoundly inhibited in macrophages upon classical activation, and a considerable part of this inhibition is NO-dependent. Although the data suggest an important role of RNS-mediated lipoic modifications in driving this inhibition, several other potential contributing mechanisms are worth considering. First, it is possible that the lipoic arm may be removed from PDHC and OGDC’s E2 subunit, SIRT4 is the only enzyme known to be able to catalyze de-lipoylation. We found that in macrophages after acute stimulation, Sirt4 expression decreased substantially, then gradually recovered over time (Supplementary Fig. 5). This is opposite to the trend in PDHC inhibition and therefore unlikely to drive the loss of functional lipoic arm. It is also possible that synthesis or conjugation of the lipoic group may be reduced. Such mechanisms would take effect only after the protein containing the already installed lipoic arm has been turned over. It has been shown that in phagocytes, PDHC has a half-life of 90 h. Therefore, this mechanism is unlikely to be a driving factor in the strong inhibition of PDHC and OGDC occurring soon after iNOS induction, but might make some contribution at later time points upon continual stimulation. NO production may also lead to an increase in other related reactive species such as ROS, which can further contribute to the inhibition of PDHC and OGDC. Finally, mechanisms targeting other subunits of PDHC or OGDC have been shown to also regulate their activity. Our previous work showed that E1 subunit phosphorylation makes a minor contribution to PDHC inhibition in activated macrophages, likely explaining the small portion of PDHC inhibition that cannot...
be fully recovered by iNOS knockout. Interestingly, a recent report identified that the E3 subunit of PDHC can be nitrosylated (the specific cysteine site was not identified), which inhibits its activity in activated macrophages. We hypothesize that because the normal function of the E3 subunit is to oxidize the lipoic arm using a Cys–Cys active site (Fig. 4a), it is likely that the E3 subunit can become modified on the catalytic cysteine via trans-nitrosylation with an NO-modified lipoic arm. This possible mechanistic connection between the E2 lipoic and E3 cysteine modifications merits further investigation, and could have synergizing effects that influence the efficiency, kinetics, and reversibility of RNS-mediated PDHC and OGDC inhibition.

In this study, we investigated the implications of NO-driven PDHC and OGDC inhibition in macrophages. However, the relevance of this mechanism may extend to a variety of cell types, including other cells that can produce NO, such as endothelial cells and neurons, and cells exposed to NO in the microenvironment. This mechanism might also apply to other lipoic arm-dependent enzymes including another mitochondrial α-ketoacid dehydrogenase, BCKDC, and the glycine cleavage system, which controls branched-chain amino acid oxidation and mitochondrial one-carbon metabolism, respectively. Regulation of these enzymes has been shown to be critical for energy homeostasis, proliferation, differentiation and other cellular functions in various cell types, and has been implicated in numerous prevalent diseases. The discoveries presented here therefore point to a broadly relevant novel mechanism for RNS to impact cellular physiology via inhibition of these key metabolic enzymes.

Online content
Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/s41589-022-01153-w.

References
41. Tannahill, G. M. et al. Succinate is an inflammatory signal that induces IL-1β through HIF-1α. Nature 496, 238–242 (2013).
Methods

Cell culture

RAW 264.7 cells (ATCC) were cultured in RPMI 1640 with 25 mM HEPES, 1% penicillin/streptomycin and 10% FBS (dialyzed FBS was used for the metabolite extraction experiments) at 37 °C and 5% CO2. To stimulate the cells, 50 ng ml−1 LPS (Escherichia coli 0111:B4, Sigma) and 10 ng ml−1 recombinant mouse IFN-γ (R&D Systems) were added to the media.

Murine BMDMs were isolated from wild-type C57BL/6 mice or B6.129P2-Nos2 tm1Lau/J (Nos2−/−) mice (Jackson Lab), as indicated. Mice were bred and maintained according to protocols approved by the University of Wisconsin-Madison Institutional Animal Care and Use Committee. Mice were group housed on a standard 12 h light/dark cycle, the environmental conditions were maintained thermostatically at 18–23 °C with 40%–60% humidity, and mice were fed ad libitum and had continual access to drinking water. Bone marrow cells were harvested from femurs and tibia of 6–12-week-old mice (male and female). Cells were differentiated in RPMI 1640 containing 25 mM HEPES, 1% penicillin/streptomycin, 10% FBS and 20% L929 conditioned media as previously described[20]. From 3 d post isolation, media were changed every day until 7 d post isolation. Cells were then plated for experiments at 2.5 × 105 cells ml−1 in RPMI 1640 containing 25 mM HEPES, 1% penicillin/streptomycin, 10% FBS (dialyzed used for metabolite extraction experiments) and 20 ng ml−1 recombinant mouse macrophage colony stimulating factor (R&D Systems). To stimulate BMDM, cells were incubated with 50 ng ml−1 LPS (E. coli 0111:B4, Sigma) and 30 ng ml−1 recombinant mouse IFN-γ (R&D Systems).

To avoid nutrient depletion, media for both RAW 264.7 cells and BMDMs were refreshed every day until collection. For continual stimulation experiments, LPS and IFN-γ were maintained in the media throughout. For acute stimulation experiments, cells were cultured with LPS and IFN-γ for 2 h, after which stimuli were removed, cells were washed with Dulbecco’s PBS (dPBS), and cell culture was continued in fresh media without stimuli for the remaining time course.

In experiments in which cells were treated with iNOS inhibitor or NO donor, the following chemicals were added: the iNOS inhibitor 1400W (Sigma, 80 μM) and the NO donor DETA NONOate (Cayman Chemical, 200 μM). Potential cellular toxicity of DETA NONOate was determined by Cytotox Green staining using an Incucyte live cell imager and analysis software (S3 2019, Sartorius).

For experiments involving stable isotopic tracing, cells were incubated with media containing [U-13C]glucose, [1,2-13C]glucose or [5-13C]glutamine (Cambridge Isotopes), which replaces the unlabeled glucose or glutamine in regular media at the same concentration. Cells were cultured with labeled media for 24 h before collection. Data from labeling experiments was adjusted for natural abundance of 13C.

Generation of Nos2−/− cells

To knockout Nos2 in RAW 264.7 cells, 2 × 106 cells were transfection via electroporation with 1 μM fluorescent trans-activating CRISPR RNA (tracrRNA, ITT, catalog no. ATTO550), 1 μM CRISPR RNA targeting mouse Nos2 (crRNA, GTGACGGCAACATGACTTCT, IDT Design ID: Mm.Cas9.NOS2.1.AA) and 1 μM Hifi Cas9 enzyme (IDT, catalog no. 1081060) in 100 μl of Nucleofector Solution V plus supplement (Lonza, catalog no. VCA-1003), using the preprogrammed electroporation protocol D-032 on Nucleofactor II/2b. Cells were immediately plated on a 35-mm plate. Sixteen hours after transfection, cells positive for fluorescent tracrRNA were single-cell sorted by FACS (BD FACSaria III) onto a 96-well plate in 50% RAW 264.7 conditioned media. Single-cell colonies were expanded and subsequently screened for the lack of NO production following LPS + IFN-γ stimulation by measuring the appearance of nitrite in the media using a Greiss Reagent Kit (Promega, catalog no. G2930). Positive hits (colonies with high viability but with no nitrite production upon stimulation) were further validated by western blot for iNOS after 24 h stimulation with LPS + IFN-γ.

Metabolite extraction

To extract intracellular metabolites, cells were washed three times with dPBS and metabolites were extracted with cold LC – MS grade 80:20 methanol/H2O (v/v). Samples were dried under nitrogen flow and subsequently dissolved in LC – MS grade water.

Liquid chromatography mass spectrometry analysis of small molecules

For the analysis of cellular metabolites or chemical reactions between small molecules (the reaction between LA or DHLA with RNS, or the reaction between CoA and RNS), samples were analyzed using a Thermo Q-Exactive mass spectrometer coupled to a Vanquish Horizon UHPLC. Analytes were separated on a 100 × 2.1 mm, 1.7 μm Acquity UPLC BEH C18 Column (Waters), with a 0.2 ml min−1 flow rate and with a gradient of solvent A (97:3 H2O/methanol, 10 mM TBA, 9 mM acetic acid, pH 8.2) and solvent B (100% methanol). The gradient is: 0 min, 5% B; 2.5 min, 5% B; 17 min, 95% B; 21 min, 95% B; 21.5 min, 5% B. Data were collected in full-scan negative mode. Setting for the ion source were: 10 aux gas flow rate, 35 sheath gas flow rate, 2 sweep gas flow rate, 3.2 kV spray voltage, 320 °C capillary temperature and 300 °C heater temperature.

The metabolites reported here were identified based on exact m/z and retention times determined with chemical standards. Data were analyzed with MAVEN[31]. When ‘Normalized ion Count’ is reported, total ion count values have been normalized to the protein content of that condition (as determined by BCA assay). When ‘Relative Abundance’ is reported, normalized ion count values have been normalized relative to unstimulated (0 h) controls.

Analysis of the reaction between LA/DHLA and RNS

LA (Cayman Chemical) or DHLA (Sigma-Aldrich) was incubated with the NO donors, GSNO, DPTA NONOate and PAPA NONOate (Cayman Chemical) at room temperature in 20 mM sodium phosphate reaction buffer for 1 or 3 h, as indicated in figure legends. At the end of incubation, the reaction mixture was diluted in LC – MS grade methanol and immediately injected onto the LC – MS using the method outlined in the section ‘Liquid chromatography mass spectrometry analysis of small molecules’. To identify major products from the reaction between DHLA and RNS, LC – MS features were pulled from untargeted analysis of control (DHLA incubated without NO donor) and NO donor-treated samples. The features were systematically compared to find major peaks present at significantly higher levels in NO donor-treated samples, but not in control. These peaks were then clustered based on retention time and chromatographic profile to identify groups of unique chemical species and their parent peak (because each compound can give many LC – MS features that are isotopic peaks or adducts of the parent compound). The formulas were identified based on exact mass and the isotopic distribution, especially the natural S34 peak and C13 peaks that indicate their compositions.

Analysis of reaction between lipoylated E2 peptide and NO donor

Dihydrolipooylated E2 peptide, LSEGDLLEIETDK(dihydrolipo)ATIG-FEVQEEYLAK (>90% purity) was synthesized by GenScript. Because some of the dihydrolipo moiety would spontaneously oxidize to the lipoyl moiety in solution, to reduce the disulfide bond before incubation with NO donors, the peptide (50 μM in 20 mM sodium phosphate buffer) was reduced using 25 mM tris(2-carboxyethyl)phosphine (70 °C for 20 min), and the tris(2-carboxyethyl)phosphine was then removed by stage-tip. Briefly, stage-tips were assembled by layering C18 Empore reversed-phase extraction disks (3 M) into the bottom of a 200-μl tip using a 16-gauge needle and plunger. Tips were conditioned with 100 μl of 100% acetonitrile (ACN) (2,000g, 1 min) followed by 100 μl of 0.5% trifluoroacetic acid (TFA) (2,000g, 1 min). Reduced peptide sample was added to top of the stage-tip and then centrifuged at 500g for 2 min.
The stage-tip was then washed four times with 150 μl of 0.5% TFA/5% ACN (2,000g, 2 min), and the sample was eluted using 100 μl of 70% ACN/0.5% TFA (2,000g, 3 min). The sample was then diluted in reaction buffer (20 mM sodium phosphate buffer containing 3 mM CoA). NO donors (GSNO, DPTA NONOate or PAPA NONOate) were added to the solution, incubated at room temperature for 1.5 h and subsequently analyzed by LC–MS.

Peptides were separated on a 100 × 2.1 mm, Accucore Vanquish UHPLC C18+ column (Thermo), with a flow rate of 0.25 ml min⁻¹ and a gradient of solvent A (5:95 H₂O/ACN) and solvent B (0.1% formic acid (FA)). The gradient is: 0 min, 90% B; 2 min, 90% B; 14 min, 1% B; 15 min, 1% B; 16 min, 90% B; 20 min, 90% B. Data were collected on a positive mode with full scan/ddMS² (loop count: 3, isolation window: 2 m/z, fragmentation with a stepped NCE: 20, 25, 30) and analyzed using XCalibur v.4.0.

**SNO-CoA and EtCys-SNO synthesis**

SNO-CoA and EtCys-SNO were freshly prepared following previously established protocols²⁻³,⁴ by reacting equal volumes of a 0.1 M CoA or cysteine ethyl ester in 1 M HCl with 0.1 M NaN₂O₃, in water containing 100 μM EDTA and 100 μM DPTA.

**Activity assays of PDHC and OGDC in cell lysate**

PDHC activity in cell lysate was analyzed using a pyruvate dehydrogenase enzyme activity microplate assay kit (Abcam), as per the manufacturer’s instructions. This kit measures PDHC activity by monitoring pyruvate-dependent NADH production. The NADH level was measured by absorbance of NADH-coupled dye (450 nm) using a BioTek Epoch2 plate reader. Data were analyzed using Gen5 TS v.2.09 software.

To evaluate OGDC activity, mitochondria were isolated and the α-KG-dependent succinyl-CoA production rate in mitochondrial lysate was measured using LC–MS. To isolate mitochondria, cells were lysed in hypotonic lysis buffer (20 mM Tris buffer pH 7.4, 1 mM EDTA with phosphatase and protease inhibitors (Pierce protease and phosphatase inhibitor tablets)) and incubated on ice for 30 min. Lysate was then homogenized using a dounce homogenizer and separated via centrifugation at 700g, 4 °C, for 10 min, in a mannitol sucrose solution (440 mM mannitol/140 mM sucrose, 20 mM Tris, 1 mM EDTA, pH 7.4). The mitochondrial fraction was resuspended in hypotonic lysis buffer. Mitochondrial lysate (30 μg protein) was diluted in 200 μl of assay buffer (1 mM MgCl₂, 400 μM thiamine diphosphate, 50 mM HEPES, 10% glycerol, 0.05% BSA) and combined with substrates (α-KG, CoA, NAD⁺). Production of succinyl-CoA was then monitored by LC–MS by injecting the reaction mixture into LC–MS grade methanol every 5–7 min over a 20–20 min time course. To measure succinyl-CoA, a similar method was used as indicated above in the section ‘Liquid chromatography mass spectrometry analysis of small molecules’; however, the gradient was accelerated for efficiency. The gradient is: 0 min, 5% B; 0.5 min, 5% B; 1 min, 30% B; 10 min, 75% B; 10.5 min, 95% B; 11 min, 95% B; 11.5 min, 95% B. The mean velocity of the reaction was blanked to a control containing no α-KG in the substrate solution and normalized relative to unstimulated or untreated control.

To investigate the ability of NO to inhibit PDHC or OGDC activity in isolated lysate, cell lysate (isolated using methods above) was incubated with NO donors at room temperature before activity measurement. The following NO donors were used: GSNO (Cayman Chemical), DPTA NONOate (Cayman Chemical) and EtCys-SNO (synthesized as above). The reversibility of RNS-mediated inhibition was tested by treating the lysate with an excess of DTT (10 mM) or buffer control at room temperature for 30 min before measuring activity.

At the end of incubation, the reaction solution was further diluted 1:20 in assay solution containing thiamine pyrophosphate (100 μM), CoA (1–5 μM), pyruvate (1–5 mM) and NAD⁺ (2.5–50 mM). The concentrations of the substrates in assay conditions were chosen so that: (1) all substrates are at saturating levels so the maximal enzyme activity is measured; (2) the substrates added in assay buffers are in excess of any carried over substrates added during the incubation period (after the 1:20 dilution), so the variation in the final substrate concentrations in assay conditions across samples are negligible; and (3) the CoA level added in the assay condition is in excess of any leftover NO donor, so possible consumption of CoA by reaction with RNS would not significantly affect the assay. This was further verified by LC–MS analysis of the reaction mix. In experiments in which large amounts of acetyl-CoA were incubated with purified enzyme to test its protection against SNO-CoA-mediated inhibition, varying levels of acetyl-CoA were added back into the assay solutions after the incubation period, such that in the assay condition, the concentration of acetyl-CoA was even across samples to control for the possible effect of acetyl-CoA as a competitive inhibitor of PDHC.

PDHC activity was measured by the rate of NADH absorbance (340 nm) increase using a BioTek Epoch2 microplate reader. NADH production was read continuously, and mean velocity values were calculated from a linear portion of the curve (up to first 10–30 min depending on the experiment). Data were analyzed using Gen5 TS v.2.09 software.

**Gel electrophoresis and immunoblotting**

Whole-cell lysate samples were prepared by lysing cells in RIPA buffer with phosphatase and protease inhibitors (Pierce protease and phosphatase inhibitor tablets) after washing three times with dPBS. The protein content of the lysate was quantified using a BCA assay kit (Thermo Fisher Scientific). Whole-cell lysates or purified PDHC reactions were separated on 4–12% Bolt Gel (Thermo Fisher Scientific) after heat denaturation in sample buffer (Thermo Fisher Scientific). No reducing buffer was added to samples when probing for the lipoic arm to minimize the potential perturbation of thiol modifications on proteins. DTT was added to sample buffer when probing for other targets. Proteins were subsequently transferred to a 0.2-μm nitrocellulose membrane. Protein loading and transfer efficiency was determined using Revert total protein stain (Li-Cor). Membranes were blocked in 5% nonfat milk in TBS-T buffer and probed with the following primary antibodies at a 1:2000 dilution: anti-iNOS (Thermo Fisher Scientific), anti-OGDC E2 (DLST; Abcam, catalog no. ab66511), anti-OGDH E2 (DLST; Abcam, catalog no. ab187699) and anti-NOSX (Thermo Fisher Scientific, catalog no. PA5-17100). Primary antibody incubation was followed by incubation with Li-Cor secondary antibodies (goat anti-rabbit 800CW, goat anti-mouse 680RD) at a 1:10,000 dilution. Membranes were imaged with a Li-Cor Odyssey CX infrared imaging system and quantified using Image Studio Lite software. On those gels blotted for lipoylated, two major bands are observed at ~70 and ~50 kDa. The 70 kDa band matches the expected molecular mass of DLAT based on the sequence and band position of the total DLAT blot, although it may also overlap with lipoylation on E2E3BP, which is of a similar expected molecular mass. The 50 kDa band matches the expected molecular mass of DLST and the band position of total DLST blot, although this molecular mass can possibly overlap with lipoylation on BCKDC’s E2 subunit, dihydrolipoamide branched-chain transacylase.
In-gel digestion and liquid chromatography mass spectrometry analysis

In-gel digestion was performed to target and separate the PDHC-E2 protein for MS analysis. Some 30 μg of Hap1 or RAW 264.7 protein lysate (quantified by BCA) was separated by SDS–PAGE. The gel was stained by AcquaStain Protein Gel Stain and protein bands corresponding to the molecular mass of PDHC-E2 were sliced and cut into pieces. Gel slices were placed in tubes for destaining with 30% ethanol, followed by dehydration with ACN and overnight digestion with 10 ng μl⁻¹ trypsin/LysC protease in 100 μM Tris buffer. Digestion was stopped by adding 5% FA and the supernatant was transferred to new tubes. Further peptide extraction buffer of 1% FA in ACN/H₂O (60:40, v/v) was added to the gel slices and aspirate to combine with previous supernatant after 10 min incubation. Extracted peptides were dried in SpeedVac and resuspended in 0.1% trifluoroacetic acid. Samples were desalted with C18 Omix tips before loading into the LC–MS system for analysis.

LC separation was performed using a Thermo Ultimate 3000 RSLCnano system. A 25 cm EASY-Spray PepMap C18 column (250 mm × 75 μm, 2 μm) was used at a flow rate of 300 nl min⁻¹ with mobile phase A consisting of 0.1% FA in H₂O, and mobile phase B consisting of 0.1% FA in ACN/H₂O (80:20, v/v). An EASY-Spray source was used and temperature was set to 35 °C. Each sample was run with a 150 min gradient starting at 3% B for 4 min, increased to 25% B over the next 69 min, then further increased to 40% B over another 37 min, followed by 35 min at 99% B and decreased back to 3% B for equilibration for 5 min. An Acclaim PepMap C18 HPLC trap column (20 mm × 75 μm, 3 μm) was used for sample loading. MS detection was performed with Thermo Exploris 240 Orbitrap mass spectrometer in positive mode. The source voltage was set to 1,800 V, the ion transfer tube temperature was set to 275 °C and the RF lens was set at 70%. Full MS spectra were acquired from m/z 350 to 1,400 at an Orbitrap resolution of 15,000, HCD collision energy of 2. The intensity threshold was 1 × 10⁵. Dynamic exclusion was 30 s with the exclusion of 28% and auto maximum ion injection time. Data-dependent acquisition was performed at a cycle time of 3 s for precursors with a charge state of 2–6 at an isolated width of 2. The intensity threshold was 1 × 10⁵. Dynamic exclusion was 30 s with the exclusion of isotopes. Other settings for data-dependent acquisition include Orbitrap resolution of 15,000, HCD collision energy of 28% and auto maximum ion injection time.

Raw MS data files were analyzed by Proteome Discoverer v.2.5.0.400. A Sequest HT search engine was utilized for searching against either a human (Hap1 samples) or mouse (RAW 264.7 samples) protein database from UniProt. Dynamic modifications included in the search are: Met oxidation (+15.995 Da), Lys dihydrolipoylation (+42.011 Da), N-terminal acetylation (+42.011 Da), N-terminal Met loss (~131.040 Da) and N-terminal Met loss + acetylation (~89.030 Da). The minimum peptide length was set to six amino acids. Precursor mass tolerance was 10 ppm and fragment mass tolerance was 0.02 Da. A Minora feature detector was used for peak detection in the processing step. Feature mapper and precursor ion quantifier nodes were used in the consensus step for protein and peptide quantification.

Statistical analyses

Statistical analyses were conducted using GraphPad Prism 9.0 software, with each respective statistical test listed in the corresponding figure legend.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

Source data are provided with this paper.

Code availability

No custom code was used in this study.

References


Acknowledgements

We thank M. Marletta at University of California, Berkeley for helpful discussions. This work was supported by National Institutes of Health (NIH) award R56 AI158958 (J.F.), National Research Service Award Individual Predoctoral Fellowship F31AI152280 (G.L.S.), also in part by funds from the BJC Investigator Program (D.J.P.) and NIH award R35 GM131795 (D.J.P.).

Author contributions

J.F. and G.L.S. conceptualized the study and designed the experiments in discussion with other authors. S.V.J. performed BMDM experiments. N.L.A. generated Nos2−/− RAW 264.7 cells and performed some analyses on these cells. Z.F. performed the measurement of the unlipoylated DLAT in RAW 264.7 and HAP1 cells under the supervision of D.J.P. G.L.S. performed all remaining experiments. G.L.S. and J.F. wrote the manuscript. G.L.S., D.J.P. and J.F. edited the manuscript with help from all authors.

Competing interests

The authors declare no competing interests.

Additional information

Extended data is available for this paper at https://doi.org/10.1038/s41589-022-01153-w.

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41589-022-01153-w.

Correspondence and requests for materials should be addressed to Jing Fan.

Peer review information Nature Chemical Biology thanks James Nathan, Ashley Solmonson and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Reprints and permissions information is available at www.nature.com/reprints.
Extended Data Fig. 1 Loss of functional lipoic arm in conditions with high citrulline accumulation. Intracellular accumulation of the iNOS product citrulline, total DLAT level, and lipoic arm status in RAW 264.7 cells and murine bone marrow derived macrophages (BMDM) treated with various combinations of LPS, IFNγ and the iNOS inhibitor, 1400W. Bar graph and error bars represent mean ± SD, n=3 distinct samples (in each of the following two conditions, BMDM +IFNγ and RAW 264.7 + LPS + IFNγ + 1400W, citrulline was not detected in one of the 3 samples, so two dots are shown). ND indicates not detected. Data were analyzed using one-way ANOVA followed by Tukey’s post hoc test. Those bars not sharing a letter are significantly different (p<0.05) from one another. Exact P-values for each comparison are available in Source Data. Western blot data is representative of two independent experiments.
Extended Data Fig. 2 | Remodeling of glucose metabolism through TCA cycle in LPS+IFNγ stimulated BMDM is largely NO dependent. a. iNOS level in wild-type and Nos2−/− BMDMs stimulated with LPS+IFNγ for indicated time. α-tubulin levels are shown as a loading control. b. The labeling patterns of acetyl-CoA, citrate, and succinate after incubation with 1,2-13C-glucose tracer for 24h in wild-type or Nos2−/− BMDM stimulated with LPS+IFN-γ for indicated time. All bars and error bars represent mean ± SD, (n=3 distinct samples). Statistical comparison (ANOVA followed by Tukey's post-hoc test) between each labeled form is provided in Source Data.
Extended Data Fig. 3 | SNO-CoA delivers RNS modifications to the lipoic arm. a–b. The decrease in CoA level (a) and the appearance of SNO-CoA (b) over time after CoA was mixed with NO donor PAPA NONOate or GSNO at indicated ratio. Statistical difference between each time point comparing to time 0 was determined by Dunnett’s multiple comparisons tests. NS specifies not significant (p>0.05), * signifies p≤0.05, ** signifies p≤0.01. Color of significance indicator corresponds to respective condition with the same color. Exact P-values for each comparison are available in Source Data. Symbol and error bars represent mean ± SD, n=3 distinct samples. TIC, total ion count. c. The activity of purified PDHC after 3h incubation (RT) with ± 200µM SNO-CoA ± 200µM pyruvate ± 200µM NADH, as indicated on figure. d. The activity of purified PDHC after 1h incubation (RT) with 200µM SNO-CoA, 200µM NADH and acetyl-CoA at various doses as indicated. After incubation period and immediately prior to activity measurement, varying amount of acetyl-CoA was added to samples to even out the final acetyl-CoA concentration across all reactions. c–d. Bars and error bars represent mean ± SD, n=3 distinct samples. Data were analyzed using one-way ANOVA followed by Tukey’s post hoc test. Those bars not sharing a letter are significantly different from each other (p<0.05). Exact P-values for each comparison are available in Source Data.
Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
  - Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted
  - Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen’s d, Pearson’s r), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection

- XCalibur 4.0 software for LCMS data; Gen5 TS 2.09 software for Biokar microplate reader data; ImageStudio Lite Ver 5.2 (Licor) for western blot imaging; IncuCyte S3 2019, Sartorius for capturing live cell images

Data analysis

- Graph Pad Prism 9.0 were used to perform statistical analyses; Maven version 6.2 (build 682) and XCalibur 4.0 were used to analyze LCMS data; ImageStudio Lite Ver 5.2 was used for western blot analysis; IncuCyte S3 2019, Sartorius for analyzing live cell images

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. Git-Hub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

Source data files are provided along with the manuscript.
Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences
- Behavioural & social sciences
- Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

<table>
<thead>
<tr>
<th>Sample size</th>
<th>No sample size calculation was performed prior to experiments; sample sizes were chosen based on typical standard in the field.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data exclusions</td>
<td>No data was excluded from successfully executed experiments with the exception of Figure 3a and 3c [R3] where a replicate of the DPTA treated DHLA was excluded as an outlier using Grubb’s test (P=0.1), details shown in Source data</td>
</tr>
<tr>
<td>Replication</td>
<td>All experiments have been successfully repeated at least twice</td>
</tr>
<tr>
<td>Randomization</td>
<td>Samples were randomly allocated to each treatment group</td>
</tr>
<tr>
<td>Blinding</td>
<td>Experiments were not conducted with blinding. Blinding was not possible as frequently one person was responsible for carrying out each experiment from beginning to data analysis.</td>
</tr>
</tbody>
</table>

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

<table>
<thead>
<tr>
<th>Materials &amp; experimental systems</th>
<th>Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>n/a</td>
<td>Involved in the study</td>
</tr>
<tr>
<td>☐ Antibodies</td>
<td>☒ ChIP-seq</td>
</tr>
<tr>
<td>☒ Eukaryotic cell lines</td>
<td>☒ Flow cytometry</td>
</tr>
<tr>
<td>☒ Palaeontology and archaeology</td>
<td>☒ MRI-based neuroimaging</td>
</tr>
<tr>
<td>☐ Animals and other organisms</td>
<td></td>
</tr>
<tr>
<td>☒ Human research participants</td>
<td></td>
</tr>
<tr>
<td>☒ Clinical data</td>
<td></td>
</tr>
<tr>
<td>☒ Dual use research of concern</td>
<td></td>
</tr>
</tbody>
</table>

Antibodies

- anti-HIF-1α (clone D2U3T, CST 14179), anti-α-tubulin (Abcam ab7291), anti-PDH E2 (DLAT, Abcam ab66511), anti-OGDC E2 (DLST, Abcam, ab187699) anti-lipoic acid (Carbiochem, 467695), anti-iNOS (Thermofisher PAS-17100), goat anti-rabbit 800CW (Lcor, 926-32211) goat anti-mouse 680RD (Lcor, 926 68070) - all were used at a 1:1000 dilution

Validation


Eukaryotic cell lines

Policy information about: cell lines

<table>
<thead>
<tr>
<th>Cell line source(s)</th>
<th>RAW 264.7 (ATCC® TIB-71™)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Authentication</td>
<td>RAW 264.7, which is a murine cell line, was not authenticated</td>
</tr>
<tr>
<td>Mycoplasma contamination</td>
<td>RAW 264.7 cell line regularly tested negative for mycoplasma</td>
</tr>
<tr>
<td>Commonly misidentified lines [see CIAC register]</td>
<td>no commonly misidentified cell lines were used</td>
</tr>
</tbody>
</table>
Animals and other organisms

Policy information about studies involving animals: ARRIVE guidelines recommended for reporting animal research

<table>
<thead>
<tr>
<th>Laboratory animals</th>
<th>For isolation of BMDM the following animals were used:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Mus musculus</td>
<td></td>
</tr>
<tr>
<td>Strains: C57BL/6J and B6.129P2-Nos2tm1Lau/J (homozygous)</td>
<td></td>
</tr>
<tr>
<td>Age: 6-12 weeks of age</td>
<td></td>
</tr>
<tr>
<td>Sex: male and females</td>
<td></td>
</tr>
<tr>
<td>Mice were group housed on a standard 12h light/dark cycle, the environmental conditions were maintained thermostatically between 18-23°C with 40-60% humidity and mice were fed ad libitum and had continual access to drinking water.</td>
<td></td>
</tr>
</tbody>
</table>

| Wild animals | study did not involve wild animals |
| Field-collected samples | study did not involve field-collected samples |
| Ethics oversight | Mice were bred and maintained according to protocols approved by the University of Wisconsin-Madison Institutional Animal Care and Use Committee |

Note that full information on the approval of the study protocol must also be provided in the manuscript.